

REMARKS

Claims 17-23 are pending. Claim 17 has been withdrawn pending the Examiner's action in the instant response. Claims 18-23 have been added. Claims 1-16 have been cancelled.

The subject matter in cancelled claim 10, directed to a specific bicyclic oligopeptide has been rewritten into new claim 18. The subject matter of claims 11-15 have been rewritten into new claims 19-23 which are dependent on claim 18. Since no new matter has been added by way of amendment entry the amendment is hereby requested.

Rejections under 35 U.S.C. §102

The Examiner rejected claims 1-3, 7-9, 11 and 12 as being anticipated by US 6,211,145. While applicant does not yield to this rejection applicant has cancelled these claims in the interest of advancing prosecution of this case.

Rejections under 35 U.S.C. §112

The Examiner rejected claims 1-9 and 11-15 for failing to comply with the written description requirement. Claims 1-9 and 11-15 have been cancelled.

Rejections under §101

The Examiner rejected claims 1-3 and 7-12 as being directed to non-statutory subject matter. The rejected claims have been cancelled and the added claims include the limitation that the recited compositions be "purified." A method of isolation is disclosed in the specification at page 4, line 3-20.

Rejections under 35 U.S.C. §112

The Examiner rejected claims 1-9 and 11-15 as failing to comply with the written description requirement. These claims have been cancelled.

Rejections under 35 U.S.C. §112


The Examiner rejected claim 10 as being indefinite. In particular, the Examiner objected to the use of the symbol "[xxxxxxxxxxxxxxxxxxxxxxxxxxxx]" in SEQ ID No.

1. Claim 10 has been cancelled and Claim 18 uses the symbol "[-----
-----]" This symbol graphically depicts the point of attachment between the Gly¹ and the β -carboxylate group of Asp⁹ as recited in the claim.

If the Examiner feels that a telephone interview would be helpful in advancing prosecution of this application, the Examiner is invited to contact the attorney below.

Applicant request that any subsequently filed reply requiring a petition for an extension of time for its timely submission be treated as if it incorporated such petition for an extension of time pursuant to the provisions of 37 C.F.R. § 1.136(a)(3) and hereby authorizes that any fees due in connection therewith be charged to Deposit Account No. 02-2955.

Respectfully submitted,




David Dow
Attorney for Applicant(s)
Reg. No. 46,124

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 791-6214

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On November 10, 2005



By: David Dow
Reg. No. 46,124